Full Archive

This is just the beginning.

As we predicted after their disastrous earnings call Tandem has implemented a significant reduction in force. While the exact numbers have not been made public, we believe this is just the first in a series of cost reductions. We also anticipate that it won’t be long before more changes come along including a new senior management team. Simple put the mistakes made by management have come home to roost and...

The possible play for Abbott

Now that Abbott has “cleared” the AID hurdle for Libre questions abound as to what’s next. As we noted yesterday Abbott could buy either Insulet or Tandem. Keep in mind Abbott has two goals here; increase Libre sales and stymie Dexcom from gaining more users. Abbott has also made it clear they are not opposed to acquisitions. The question becomes are Insulet and Tandem the only options here. Given that 61%...

The real cage match.

This really shouldn’t surprise anyone, but last Friday Abbott filed suit against Dexcom over the G7. Frankly this suit is not a surprise as it’s Abbott and Dexcom who are involved in a real-world cage match. IP suits are all part of the game, a game in which the only winners are the patent attorneys and expert witnesses. These suits aren’t ever settled quickly which means it likely will years...

Have fun, do good.

Not sure how many of my readers are aware of a spat going on via LinkedIn. Without going into all the gory details this all started when I noted in a response to a post that the insulin companies are not directly responsible for the out-of-pocket cost of insulin. That you cannot draw a straight line from the companies to what the patient pays out of pocket. It seems that I...

Won’t change much.

This morning Abbott received word that the FDA has cleared the Libre 2 and Libre 3 for integration into an automated insulin dosing (AID) system. Per their press release – “Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems. Abbott modified the...

Layoffs, investigation what’s up at Abbott?

Since most people aren’t aware of Abbott’s history in CGM let’s go backward before we go forward. In February of 2004 when Abbott acquired Therasense for $1.2 Billion hidden in this deal was the Navigator. Keep in mind that back in 2004 BGM ruled the glucose monitoring world and CGM was still a dream. Yet CGM was coming, and the Navigator was considered the best of the bunch. In June 2005...

It won’t help.

Before we get into the gist of today’s post a short history of acquisitions in the insulin pump space. Way back in the day there were two major players MiniMed and Disetronic. Back in 2003 Roche paid $1.2 Billion for Disetronic and promptly ran the company into the ground. Not content to run just one insulin pump company into the ground Roche doubled down and in 2010 spent another $160 million...